Development of new therapeutics for castration-resistant prostate cancer treatment
Castration-resistant prostate cancer is a late stage disease and many people die of it due to lack of effective therapeutic drugs. In the current project, we propose to develop new therapeutic drug a to specifically target CRPCs common weak points, which are MCT4 and eIF4E genes proteint products that play very important roles in regulation of cancer cells energetic and protein translation pathways. The project aims to develop an antibody drug, an small molecule chemical drug and a nanoparticle drug to target MCT4 membrane protein and eIF4E transcription factor protein. If successful, the project will lead to new drug development for treating this deadly disease.